The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a ...

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...

Are you forgetting quite often? A brisk walk, dance, or climbing a few flights of stairs may be key to boosting your memory, ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

A large-scale Swedish study on Monday suggested that drinking sweetened drinks can significantly increase your risk of ...

Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma ...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of ...

South Korean biopharmaceutical firm Celltrion said Monday that it has received approval from Health Canada for Omlyclo, its omalizumab biosimilar referencing Xolair, designed to treat allergic asthma ...

Korea's pharmaceutical giant Celltrion said Monday that it has received approval from Canadian health authorities for a ...

In an era of rapid healthcare innovation, the global at-home testing market is emerging as a transformative force, offering unprecedented convenience and accessibility to individuals worldwide.

The global biosimilar monoclonal antibody market revenue was around US$ 10.6 billion in 2023 and is estimated to reach US$ 64.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 22.2 ...